Forteo

Company snapshot

Forte Bio-Pharma (also known as Forte BioPharma) is a specialty pharmaceutical company dedicated to advancing pain management through innovative in-licensing, development, and commercialization of novel medications. Founded in 2018 by a team with over 90 years of combined pharmaceutical expertise, we are committed to delivering unique dosage options and improved therapies for unmet medical needs.

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 US patent(s) indexed to this assignee profile.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Forteo. Not investment advice.

• Peer + 0 momentum

  Nektar Therapeutics UK

  TA overlap score 31.4

• Peer + 0 momentum

  Incyte

  TA overlap score 30.6

• Peer + 0 momentum

  Aclaris Therapeutics

  TA overlap score 26.6

• Peer + 0 momentum

  Arcutis Biotherapeutics

  TA overlap score 25.4

Recent activity

Latest pipeline, patent, and corporate events for Forteo.

1. May 23, 2026 Clinical update

   FB-401 — Phase 2

2. May 23, 2026 Clinical update

   FB102 — Phase 2

3. May 23, 2026 Clinical update

   FB102 — Phase 1

4. May 23, 2026 Clinical update

   FB102 — Phase 1

5. May 23, 2026 Clinical update

   Signature Cord Prime — Phase 1

View all clinical trial activity →

• What is Forteo?

  Forteo is a pharma organization headquartered in Las Vegas, USA. Primary therapeutic focus areas include Atopic Dermatitis, Alopecia Areata, Celiac Disease, Vitiligo, Osteoarthritis, Knee. NovaPharmaNews links 5 clinical program(s), 0 drug profile(s), and 3 patent record(s) to th

• Is Forteo publicly traded?

  Forteo appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Forteo develop or market?

  No drug profiles are currently linked to Forteo. Pipeline programs may still list investigational assets.

• What are the latest developments for Forteo?

  In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Forteo focus on?

  Forteo focuses on Atopic Dermatitis, Alopecia Areata, Celiac Disease based on our analysis of their pipeline programs and drug development activities.